Documentos relacionados

1. Histone deacetylase (HDAC) inhibitor specificity determinants are preserved in a class of dual HDAC/non-covalent proteasome inhibitors.
2. Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors.
3. Research progress in proteasome inhibitor resistance to multiple myeloma.
4. Long-Term Retarded Release for the Proteasome Inhibitor Bortezomib through Temperature-Sensitive Dendritic Glycopolymers as Drug Delivery System from Calcium Phosphate Bone Cement.
5. Targeting Plasma Cells with Proteasome Inhibitors: Principles from Primates.
6. Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus.
7. Effects of invivo CXCR4 blockade and proteasome inhibition on bone marrow plasma cells in HLA-sensitized kidney transplant candidates.
8. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.
9. The Proteasome Inhibitor Bortezomib Induces p53-Dependent Apoptosis in Activated B Cells.
10. Proteasome inhibitor bortezomib stabilizes and activates p53 in hematopoietic stem/progenitors and double-negative T cells in vivo.